NCT05475574 Impact of Discontinuing Contact Precautions for Extended-spectrum β-lactamase Enterobacteriaceae in a Geriatric Unit
| NCT ID | NCT05475574 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Régional Metz-Thionville |
| Condition | Infection, Hospital |
| Study Type | INTERVENTIONAL |
| Enrollment | 954 participants |
| Start Date | 2023-03-07 |
| Primary Completion | 2029-09-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 954 participants in total. It began in 2023-03-07 with a primary completion date of 2029-09-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is an interventional multicenter prospective noninferiority non-randomized double-blind controlled before and after study. The aim of this study is to demonstrate that standard precautions alone are not inferior to contact precautions by comparing the incidence density of extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae acquired in geriatric units before and after discontinuing contact precautions.
Eligibility Criteria
Inclusion Criteria: * Adult patient (\> 65 years old) * Patient hospitalized in geriatrics during the study period * Free and informed consent obtained from the patient (or his trusted person or legal representative) within 48 hours of its admission at the geriatric unit * Patient affiliated to a social security scheme Non Inclusion Criteria: * Patient requiring contact precaution for an indication other than ESBLE (COVID-19, classical PCC excluding EBLSE, Clostridium difficile PCC, scabies PCC and BHRe PCC) on admission * Patient under legal protection * Person deprived of liberty Exclusion criteria: * Patient requiring contact precaution for an indication other than ESBL during the patient stay (COVID-19, classical PCC excluding EBLSE, Clostridium difficile PCC, scabies PCC and BHRe PCC) * Patient's stay period less than 4 days
Contact & Investigator
Noel BLETTNER, MD
PRINCIPAL INVESTIGATOR
Mercy Hospital CHR Metz Thionville
Frequently Asked Questions
Who can join the NCT05475574 clinical trial?
This trial is open to participants of all sexes, aged 65 Years or older, studying Infection, Hospital. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05475574 currently recruiting?
Yes, NCT05475574 is actively recruiting participants. Contact the research team at l.renaudin@chr-metz-thionville.fr for enrollment information.
Where is the NCT05475574 trial being conducted?
This trial is being conducted at Metz, France.
Who is sponsoring the NCT05475574 clinical trial?
NCT05475574 is sponsored by Centre Hospitalier Régional Metz-Thionville. The principal investigator is Noel BLETTNER, MD at Mercy Hospital CHR Metz Thionville. The trial plans to enroll 954 participants.